UMMS Affiliation

Department of Pediatrics

Publication Date


Document Type



Adenylate Cyclase; Adolescent; Adult; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Blood Platelets; Blotting, Western; Case-Control Studies; Cell Membrane; Child; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Fatty Acids; Genotype; Humans; Ibuprofen; Inflammation; Leukocytes; Monocytes; Neutrophils; P-Selectin; *Platelet Activation; RNA, Messenger; Reverse Transcriptase Polymerase Chain Reaction; Thromboxane A2; Time Factors; Vitamin E


Circulatory and Respiratory Physiology | Pediatrics


Cystic fibrosis (CF) is caused by a mutation of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). We examined platelet function in CF patients because lung inflammation is part of this disease and platelets contribute to inflammation. CF patients had increased circulating leukocyte-platelet aggregates and increased platelet responsiveness to agonists compared with healthy controls. CF plasma caused activation of normal and CF platelets; however, activation was greater in CF platelets. Furthermore, washed CF platelets also showed increased reactivity to agonists. CF platelet hyperreactivity was incompletely inhibited by prostaglandin E(1) (PGE(1)). As demonstrated by Western blotting and reverse-transcriptase-polymerase chain reaction (RT-PCR), there was neither CFTR nor CFTR-specific mRNA in normal platelets. There were abnormalities in the fatty acid composition of membrane fractions of CF platelets. In summary, CF patients have an increase in circulating activated platelets and platelet reactivity, as determined by monocyte-platelet aggregation, neutrophil-platelet aggregation, and platelet surface P-selectin. This increased platelet activation in CF is the result of both a plasma factor(s) and an intrinsic platelet mechanism via cyclic adenosine monophosphate (cAMP)/adenylate cyclase, but not via platelet CFTR. Our findings may account, at least in part, for the beneficial effects of ibuprofen in CF.

DOI of Published Version



Blood. 2005 Jun 15;105(12):4635-41. Epub 2005 Feb 10. Link to article on publisher's site

Journal/Book/Conference Title


Related Resources

Link to article in PubMed

PubMed ID




To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.